

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 9099
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

8 October 2013

Universal Biosensors Business Update

Key points:

- Quarterly Service Fees return to growth trajectory
- LifeScan expands Verio manufacturing capacity
- Siemens and UBI revise launch timetable for their new point-of-care coagulation testing system

Quarterly Service Fees return to growth trajectory

Universal Biosensors, Inc (ASX:UBI) today announced that its Quarterly Service Fees for the Quarter ended 30th September 2013 are up 50% on the prior comparable period, at A\$833,000.

Following the March 2013 recall of Verio meters by LifeScan, which resulted in a temporary dip in Quarterly Service Fees, this return to strong year on year growth reflects the competitive strength of the OneTouch Verio system.

UBI CEO, Paul Wright said: *"Given that the Quarterly Service Fees are a key driver of value for UBI and a direct reflection of the success of the product in the marketplace, it's exciting to see a return to a solid growth trajectory"*

LifeScan expands Verio manufacturing capacity

UBI also announced today that partner LifeScan has increased its available Verio manufacturing capacity at its Inverness production facility to around 1.5 billion test strips per annum. Including the capacity available at the UBI facility in Rowville, worldwide Verio strip manufacturing capacity now totals around 2.25 billion strips per annum

The increase in production capacity at Inverness is a validation of LifeScan's confidence in the growth of the OneTouch Verio system and reflects UBI's expectation that LifeScan will become the primary manufacturer of Verio strips in the future.

UBI CEO, Paul Wright said: *"It is exciting to see LifeScan investing further in Verio production capacity – it's a great demonstration of their commitment to the platform and their expectations for its success."*

Siemens & UBI revise launch timetable for their new point-of-care coagulation testing system

UBI, together with its partner Siemens, have revised the launch timeframe for their first point-of-care coagulation testing system, with first commercial sales now to occur in 2014.

The product, a point-of-care PT-INR testing system used to monitor the use of the oral anticoagulant drug warfarin, will be marketed internationally by Siemens. The system is in the late stages of development and has been undergoing extensive clinical testing over recent months. The decision to delay the launch, originally planned for 2013, has primarily been brought about by the challenge of recruiting sufficient patients with high INR values (necessary to demonstrate performance across a wide clinical range) within the expected timeframe.

While we are aiming for launch in the first half of 2014, UBI is working with Siemens on a range of strategies to ensure the clinical and commercial success of this product and will update the market once further testing is completed and the revised launch strategy has been better defined.

UBI Chief Executive Paul Wright, said: *"We are planning to launch a great product in an attractive market that presents one of the largest opportunities in point-of-care diagnostics globally. The joint Siemens and UBI team are*

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 9099
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

working very effectively together and we are all looking forward to achieving the first sale of a high quality point of care testing system in the near future."

With well over 7 million warfarin users globally, the professional point-of-care PT-INR market is estimated at over \$500M and growing at around 10% per annum.

Ends

Enquiries:

Paul Wright +61 3 9213 9000

Salesh Balak +61 3 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to
<http://www.universalbiosensors.com/announcements.html>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.